Annual report pursuant to Section 13 and 15(d)

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.24.1
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
12 Months Ended
Dec. 31, 2023
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

    

Year Ended December 31, 

($ in thousands)

    

2023

    

2022

Qbrexza®

$

25,410

$

26,715

Accutane®

20,168

18,373

Amzeeq

6,201

7,242

Targadox®

3,204

7,972

Exelderm®

 

2,395

 

3,463

Zilxi

 

1,962

 

2,273

Ximino®

 

287

 

4,957

Luxamend®

 

35

 

Total product revenues

$

59,662

$

70,995

Schedule of other revenue

    

Year Ended December 31,

($in thousands)

2023

    

2022

Non-refundable upfront payment from Maruho

 

$

19,000

$

Net milestone payment from Maruho

2,500

Royalties on sales of Rapifort® Wipes 2.5%

$

519

174

Total other revenue

$

19,519

$

2,674